Improving Outcomes in Early Hormone-Positive Breast Cancer
Part of Cancer clinical trials.
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- You have been diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer (cancer that hasn't spread to distant parts of the body)
- Your doctor prescribed abemaciclib for your treatment according to standard medical guidelines
- You started abemaciclib therapy between January 1, 2023 and June 30, 2025
- You do not have locally advanced or metastatic (widespread) breast cancer
- You have no medical reasons that would make abemaciclib unsafe for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether supporting patients helps them stick to their prescribed oral breast cancer treatment (abemaciclib and hormone therapy). If you're already taking this combination for early-stage breast cancer, the study team may provide extra guidance to help you stay on track.
This trial tests whether adding abemaciclib to standard hormone (endocrine) therapy can improve outcomes for certain types of advanced breast cancer. It also uses a phone app to help you and the team track side effects so problems can be caught early.
This study looks at how well a combination of two medicines (a CDK4/6 inhibitor and an aromatase inhibitor) works for people with a certain type of advanced breast cancer. It aims to gather real-world information to better understand treatment patterns and outcomes.
This study uses real-world health records to learn about outcomes in people with hormone-receptor positive, HER2-negative breast cancer who were treated with abemaciclib along with hormone (endocrine) therapy. It may help doctors better understand how well this treatment works outside of clinical trials.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
This trial tests whether a higher dose of abemaciclib (a pill that helps stop cancer cells from growing) is safe and effective when used after surgery for early high-risk breast cancer. It is for people whose cancer is hormone receptor positive and HER2 negative, and who will take it along with endocrine therapy (hormone-blocking treatment).
Hear when a new HR+/HER2- Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.